Eton Pharmaceuticals
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc., a privately held company, is focused on the development and commercialization of innovative sterile injectable product candidates utilizing the FDA 505(b)(2) regulatory pathway.96 articles about Eton Pharmaceuticals
-
Eton Pharmaceuticals Reports First Quarter 2023 Financial Results
5/11/2023
Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, reported financial results for the quarter ended March 31, 2023.
-
Eton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution, a Generic Version of Cystadane® (betaine anhydrous for oral solution)
5/10/2023
Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced the commercial availability of Betaine Anhydrous for Oral Solution 180 grams for the treatment of homocystinuria.
-
Eton Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
5/3/2023
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2023 financial results on Thursday, May 11, 2023.
-
Eton Pharmaceuticals Reports Fourth Quarter 2022 Financial Results
3/16/2023
Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended December 31, 2022.
-
Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600
3/15/2023
Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the acquisition of rare disease product candidate ET-600 from Tulex Pharmaceuticals.
-
Eton Pharmaceuticals to Report Fourth Quarter 2022 Financial Results on Thursday, March 16, 2023
3/7/2023
Eton Pharmaceuticals, Inc. today announced that it will report fourth quarter 2022 financial results on Thursday, March 16, 2023.
-
Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection
1/11/2023
Eton Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s New Drug Application (NDA) response for dehydrated alcohol injection for the proposed indication of methanol poisoning.
-
Eton Pharmaceuticals Reports Third Quarter 2022 Financial Results
11/10/2022
Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, reported financial results for the quarter ended September 30, 2022.
-
Eton Pharmaceuticals to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
11/2/2022
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2022 financial results on Thursday, November 10, 2022.
-
Eton Pharmaceuticals to Present at the LD Micro Main Event XV Conference
10/18/2022
Eton Pharmaceuticals today announced that Sean Brynjelsen, Chief Executive Officer, will present at the LD Micro Main Event XV Conference as follows: Date: Wednesday, October 26, 2022 Time: 6:00PM ET.
-
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution
9/13/2022
Eton Pharmaceuticals today announced the acquisition of betaine anhydrous for oral solution.
-
Eton Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
8/30/2022
Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjelsen, Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference.
-
Eton Pharmaceuticals Reports Second Quarter 2022 Financial Results
8/11/2022
Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, reported financial results for the second quarter ended June 30, 2022.
-
Eton Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
8/2/2022
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2022 financial results on Thursday, August 11, 2022.
-
FDA Weekly Review looks at the FDA's actions related to drug approvals, IND approvals, designations and more. Here’s a look at what happened this week.
-
Eton Pharmaceuticals Announces Sale of Hospital Products
6/24/2022
Eton sold its rights in Biorphen®, Rezipres®, and Cysteine Hydrochloride products for total payments of up to $50 million.
-
The FDA has a few target action dates for the end of the month, although PDUFA dates can sometimes seem like a moving target.
-
Eton Pharmaceuticals Reports First Quarter 2022 Financial Results
5/12/2022
Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, reported financial results for the first quarter ended March 31, 2022.
-
Eton Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
5/3/2022
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2022 financial results on Thursday, May 12, 2022.
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.